Clinical Trial Update: L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating L-TIL plus tislelizumab as first-line treatment for advanced malignant melanoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• L-TIL
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Quanli Gao | Conditions: Malignant Melanoma | Phase 2 | Status: TERMINATED